Elizabeth Bertone-Johnson

Dr. Elizabeth Bertone-Johnson


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2005 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
EBElizabeth Bertone-Johnson
Elizabeth Bertone-Johnson
WCWendy Y. Chen
Wendy Y. Chen
Michael HolickMichael Holick
Michael Holick
BHBruce W. Hollis
Bruce W. Hollis
GCGraham A Colditz
Graham A Colditz
SHSusan E. Hankinson
Susan E. Hankinson
Several lines of evidence suggest that vitamin D may reduce incidence of breast cancer, but few epidemiologic studies have addressed the relation of plasma vitamin D metabolites to the risk of this disease. We prospectively examined the relationship between plasma levels of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D] and risk of breast cancer in a case-control study nested within the Nurses' Health Study cohort. Blood samples were collected from study participants in 1989-1990. Breast cancer cases developing between blood collection and June 1, 1996, were matched to cancer-free controls on the basis of age, menopausal status, and other factors. Stored plasma samples from 701 cases and 724 controls were available for metabolite analysis. Cases had a lower mean 25(OH)D level than controls (P = 0.01), but mean 1,25(OH)2D levels were similar (P = 0.49). High levels of both metabolites were associated with a nonsignificant lower risk of breast cancer. Women in the highest quintile of 25(OH)D had a relative risk of 0.73 (95% confidence interval = 0.49-1.07; Ptrend = 0.06) compared with those in the lowest quintile. For 1,25(OH)2D, the comparable relative risk was 0.76 (95% confidence interval = 0.52-1.11; Ptrend = 0.39). For both metabolites, the association was stronger in women ages 60 years and older, but results were not statistically significant. Our findings suggest that high levels of 25(OH)D, and perhaps 1,25(OH)2D, may be modestly associated with reduced risk of breast cancer.

1 August 2009 in Nutrition Reviews
Verified
Journal Article
Open access
PDF file
EBElizabeth Bertone-Johnson
Elizabeth Bertone-Johnson
While recent laboratory-based studies have substantially advanced our understanding of the action of vitamin D in the brain, much is still unknown con

13 June 2005 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
EBElizabeth Bertone-Johnson
Elizabeth Bertone-Johnson
SHSusan E. Hankinson
Susan E. Hankinson
ABAdrianne Bendich
Adrianne Bendich
SJSusan R. Johnson
Susan R. Johnson
WWWalter C. Willett
Walter C. Willett
JMJoAnn E. Manson
JoAnn E. Manson
It is estimated that as many as 85% to 90% of premenopausal women regularly experience affective and/or physical symptoms before the onset of menses.1 While symptoms are mild in most women, 8% to 20% experience symptoms that meet the clinical definition of premenstrual syndrome (PMS),1-3 a disorder characterized by moderate to severe symptoms that substantially interfere with normal life activities and interpersonal relationships.4,5 Symptoms are limited to the luteal phase of the menstrual cycle, abate shortly after the onset of menses, and commonly include depression, irritability, fatigue, abdominal cramping, breast tenderness, and headaches.1 Women in whom affective symptoms predominate may also meet the criteria for premenstrual dysphoric disorder,6 a more severe form of PMS that is associated with significant impairment of normal functioning6,7; recent studies1,8 estimate that 5% to 8% of premenopausal women meet the criteria for premenstrual dysphoric disorder. Women presenting with symptoms are commonly prescribed oral contraceptives (OCs), gonadotropin-releasing hormone agonists, and serotonin reuptake inhibitors.9 While these therapies may be effective at treating PMS in many women, they are also associated with substantial adverse effects and can be expensive.9-11 Alternatives to hormone therapy, such as dietary supplementation, are being evaluated.

17 July 2014 in Human Reproduction
Verified
Journal Article
Open access
PDF file
EBElizabeth Bertone-Johnson
Elizabeth Bertone-Johnson
ARA. G. Ronnenberg
A. G. Ronnenberg
SHS. C. Houghton
S. C. Houghton
CNC. Nobles
C. Nobles
SZS. E. Zagarins
S. E. Zagarins
BWB. W. Whitcomb
B. W. Whitcomb
Are markers of chronic inflammation associated with menstrual symptom severity and premenstrual syndrome (PMS)? Serum levels of inflammatory markers, including interleukin (IL)-2, IL-4, IL-10, IL-12 and interferon (IFN)-γ were positively associated with menstrual symptom severity and/or PMS in young women. Chronic inflammation has been implicated in the etiology of depression and other disorders that share common features with PMS, but whether inflammation contributes to menstrual symptom severity and PMS is unknown. Cross-sectional study of 277 women aged 18–30 years, conducted in 2006–2011. Participants provided information on menstrual symptoms, lifestyle, diet, anthropometry and other factors by questionnaire and/or direct measurement, and a mid-luteal phase fasting blood sample was taken between 7 a.m. and 12 p.m. Total, physical and affective menstrual symptom scores were calculated for all participants, of whom 13% (n = 37) met criteria for moderate-to-severe PMS and 24% (n = 67) met PMS control criteria. Inflammatory factors assayed in serum included IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, tumor necrosis factor-α, granulocyte macrophage colony stimulating factor, IFN-γ and C-reactive protein. After adjustment for age, smoking status and BMI, total menstrual symptom score was positively associated with levels of IL-2 (percentage difference in women at the 75th percentile of total symptom score versus at the 25th percentile = 24.7%; P = 0.04), IL-4 (21.5%; P = 0.04), IL-10 (28.0%; P < 0.01) and IL-12 (42.0%; P = 0.02) in analyses including all participants. Affective menstrual symptom score was linearly related to levels of IL-2 (percentage difference at 75th percentile versus 25th percentile = 31.0%; P = 0.02), while physical/behavioral symptom score was linearly related to levels of IL-4 (19.1%; P = 0.03) and IL-12 (33.2%; P = 0.03). Additionally, mean levels of several factors were significantly higher in women meeting PMS criteria compared with women meeting control criteria, including IL-4 (92% higher in cases versus controls; P = 0.01); IL-10 (87%; P = 0.03); IL-12 (170%; P = 0.04) and IFN-γ (158%; P = 0.01). Our study has several limitations. While a single blood sample may not perfectly capture long-term levels of inflammation, ample data suggest that levels of cytokines are stable over time. Although we did not base our assessment of PMS on prospective symptom diaries, we used validated criteria to define PMS cases and controls, and excluded women with evidence of comorbid mood disorders. Furthermore, because of the cross-sectional design of the study, the temporal relation of inflammatory factors and menstrual symptoms is unclear. To our knowledge, this is among the first studies to suggest that inflammatory factors may be elevated in women experiencing menstrual symptoms and PMS. Additional studies are needed to determine whether inflammation plays an etiologic role in PMS. This study was funded by the Departments of Public Health and Nutrition and by a Faculty Research Grant, University of Massachusetts Amherst. No conflicts declared. N/A.

1 December 2012 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
EBElizabeth Bertone-Johnson
Elizabeth Bertone-Johnson
BWBrian W. Whitcomb
Brian W. Whitcomb
SMStacey A. Missmer
Stacey A. Missmer
EKElizabeth W. Karlson
Elizabeth W. Karlson
JRJanet W. Rich-Edwards
Janet W. Rich-Edwards

1 November 2010 in Journal of Women's Health
Verified
Journal Article
Closed access
EBElizabeth Bertone-Johnson
Elizabeth Bertone-Johnson
SHSusan E. Hankinson
Susan E. Hankinson
WWWalter C. Willett
Walter C. Willett
SJSusan R. Johnson
Susan R. Johnson
JMJoAnn E. Manson
JoAnn E. Manson
Background: Moderate to severe premenstrual syndrome (PMS) affects 8%–20% of premenopausal women and causes substantial levels of impairment, but few modifiable risk factors for PMS have been identified. Adiposity may impact risk through the complex interaction of hormonal and neurochemical factors, but it is not known if adiposity increases a woman's risk of developing PMS. We have addressed these issues in a prospective study nested within the Nurses' Health Study 2. Methods: Participants were a subset of women aged 27–44 and free from PMS at baseline, including 1057 women who developed PMS over 10 years of follow-up and 1968 controls. Body mass index (BMI), weight change and weight cycling were assessed biennially via questionnaire. Results: We observed a strong linear relationship between BMI at baseline and risk of incident PMS, with each 1 kg/m2 increase in BMI associated with a significant 3% increase in PMS risk (95% confidence interval [CI] 1.01-1.05). After adjustment for age, smoking, physical activity, and other factors, women with BMI ≥27.5 kg/m2 at baseline had significantly higher risks of PMS than women with BMI <20 kg/m2 (ptrend = 0.003). A large weight change between age 18 and the year 1991 was significantly associated with PMS risk, whereas weight cycling during this period was not. BMI was positively associated with specific symptoms, including swelling of extremities, backache, and abdominal cramping (all p < 0.001). Conclusions: Our findings suggest that maintaining a healthy body mass may be important for preventing the development of PMS. Additional studies are needed to assess whether losing weight would benefit overweight and obese women who currently experience PMS.